[Antiproliferative coated stents and intracoronary brachytherapy: common traits and differences].
Intracoronary brachytherapy is the first internationally recognized, evidence-based coronary intervention for in-stent restenosis. But the present and future role of brachytherapy is questioned by the first results of clinical trials with antiproliferative coated stents. This overview compares the status quo of both methods, concluding first practical considerations.
Silber
S
S
Kardiologische Praxis in der Klinik Dr. Müller Am Isarkanal 36 81379 München, Germany. silber@med.de
D001918:Brachytherapy; D002455:Cell Division / Q000187:drug effects / Q000528:radiation effects*; D000077407:Cilostazol; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects / Q000528:radiation effects; D013777:Tetrazoles / Q000008:administration & dosage; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome
D020099:Coated Materials, Biocompatible; D013777:Tetrazoles; D000077144:Clopidogrel; D000077407:Cilostazol; D013988:Ticlopidine